Table 4.
Association analysis of rs7044343 with RA in the replication population
| Characteristic ( n ) |
Allele frequency (%) |
Genotype frequency (%) |
T vs. C |
CC vs. TT + TC |
CC + TC vs. TT |
|||
|---|---|---|---|---|---|---|---|---|
| T | C | TT | TC | CC |
OR (95% CI) |
OR (95% CI) |
OR (95% CI) |
|
| P -value | P .-value | P -value | ||||||
| Control (701) |
631 (45.0) |
771 (55.0) |
154 (22.0) |
323 (46.1) |
224 (32.0) |
|
|
|
| RA (666) |
632 (47.4) |
700 (52.6) |
144 (21.6) |
344 (51.7) |
178 (26.7) |
1.103 |
0.777 |
1.021 |
| (0.949-1.282) |
(0.615-0.981) |
(0.789-1.320) |
||||||
| 0.201 |
0.034* |
0.877 |
||||||
| RF + (325) |
300 (46.2) |
350 (53.8) |
73 (22.5) |
154 (47.4) |
98 (30.2) |
1.047 |
0.919 |
0.972 |
| (0.869-1.262) |
(0.691-1.223) |
(0.709-1.333) |
||||||
| 0.627 |
0.563 |
0.860 |
||||||
| RF-(62) |
54 (43.5) |
70 (56.5) |
10 (16.1) |
34 (54.8) |
18 (29.0) |
0.943 |
0.871 |
1.464 |
| (0.651-1.365) |
(0.492-1.542) |
(0.727-2.948) |
||||||
| 0.754 |
0.636 |
0.286 |
||||||
| ACPA + (224) |
192 (42.9) |
256 (57.1) |
39 (17.4) |
114 (50.9) |
71 (31.7) |
0.916 |
0.988 |
1.335 |
| (0.739-1.136) |
(0.715-1.365) |
(0.905-1.970) |
||||||
| 0.425 |
0.943 |
0.2145 |
||||||
| ACPA-(101) |
103 (51.0) |
99 (49.0) |
23 (22.8) |
57 (56.4) |
21 (20.8) |
1.271 |
0.559 |
0.955 |
| (0.946-1.708) |
(0.337-0.927) |
(0.580-1.571) |
||||||
| 0.111 |
0.024* |
0.856 |
||||||
| Female Control (519) |
474 (45.7) |
564 (54.3) |
114 (22.0) |
246 (47.4) |
159 (30.6) |
|
|
|
| Female RA (458) |
410 (44.8) |
506 (55.2) |
92 (20.1) |
226 (49.3) |
140 (30.6) |
1.040 |
0.997 |
1.120 |
| (0.869-1.246) |
(0.759-1.309) |
(0.822-1.525) |
||||||
| 0.668 |
0.982 |
0.473 |
||||||
| Female RF+ (256) |
237 (46.3) |
275 (53.7) |
56 (21.9) |
125 (48.8) |
75 (29.3) |
1.025 |
0.938 |
1.005 |
| (0.829-1.268) |
(0.676-1.302) |
(0.700-1.444) |
||||||
| 0.817 |
0.703 |
0.977 |
||||||
| Female RF- (53) |
46 (43.4) |
60 (56.6) |
8 (15.1) |
30 (56.6) |
15 (28.3) |
0.912 |
0.894 |
1.583 |
| (0.610-1.365) |
(0.478-1.672) |
(0.726-3.455) |
||||||
| 0.655 |
0.725 |
0.248 |
||||||
| Female ACPA+ (158) |
133 (42.1) |
183 (57.9) |
27 (17.1) |
79 (50.0) |
52 (32.9) |
0.865 |
1.111 |
1.366 |
| (0.670-1.115) |
(0.759-1.625) |
(0.859-2.171) |
||||||
| 0.263 |
0.589 |
0.187 |
||||||
| Female ACPA- (76) |
72 (47.4) |
80 (52.6) |
14 (18.4) |
44 (57.9) |
18 (23.7) |
1.071 |
0.703 |
1.247 |
| (0.761-1.506) |
(0.401-1.231) |
(0.673-2.308) |
||||||
| 0.694 |
0.217 |
0.483 |
||||||
| Male CON (130) |
125 (48.1) |
135 (51.9) |
30 (23.1) |
65 (50.0) |
35 (26.9) |
|
|
|
| Male RA (95) |
75 (39.5) |
115 (60.5) |
16 (16.8) |
43 (45.3) |
36 (37.9) |
0.704 |
1.656 |
1.481 |
| (0.482-1.029) |
(0.939-2.921) |
(0.754-2. 908) |
||||||
| 0.070 |
0.081 |
0.254 |
||||||
| Male RF+ (54) |
42 (38.9) |
66 (61.1) |
10 (18.5) |
22 (40.7) |
22 (40.7) |
0.687 |
1.866 |
1.320 |
| (0.435-1.085) |
(0.958-3.636) |
(0.594-2.934) |
||||||
| 0.107 |
0.067 |
0.496 |
||||||
| Male RF- (9) |
8 (44.4) |
10 (55.6) |
2 (22.2) |
4 (44.4) |
3 (33.3) |
0.864 |
1.357 |
1.050 |
| (0.330-2.259) |
(0.322-5.723) |
(0.207-5.325) |
||||||
| 0.765 |
0.677 |
0.953 |
||||||
| Male ACPA+ (44) |
29 (33.0) |
59 (67.0) |
4 (9.1) |
21 (47.7) |
19 (43.2) |
0.531 |
2.063 |
3.000 |
| (0.320-0.881) |
(1.013-4.202) |
(0. 993–9.065) |
||||||
| 0.014 |
0.046 |
0.052 |
||||||
| Male ACPA- (11) | 13 (59.1) | 9 (40.9) | 5 (45.5) | 3 (27.3) | 3 (27.3) | 1.560 |
1.018 |
0.360 |
| (0.644-3.776) |
(0.255-4.055) |
(0.103-1.263) |
||||||
| 0.321 | 0.980 | 0.111 | ||||||
*P < 0.05 vs controls; RA rheumatoid arthritis; CON healthy controls; RF rheumatoid factor; ACPA anti-citrullinated proteins antibodies; OR Odds ratio; CI confidence interval.